Trace Neuroscience vs Mirador Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Launched with $101M Series A (Third Rock, Atlas, GV, RA Capital). TRCN-1023 (ASO for UNC13A mRNA splicing) entered ALS clinical testing in early 2026 — skipping healthy volunteer phase. Targets 97% of ALS patients.
About
Trace Neuroscience launched with $101 million in Series A financing from Third Rock Ventures, Atlas Venture, GV (Google Ventures), and RA Capital Management, developing TRCN-1023 — an antisense oligonucleotide (ASO) that corrects UNC13A mRNA splicing defects that have been genetically validated as a driver of ALS (amyotrophic lateral sclerosis). The company went directly to ALS patient enrollment in early 2026, bypassing the healthy volunteer phase typical of first-in-human trials, reflecting confidence in the mechanism's tolerability profile.
Raised $250M Series B (Jan 2026). $650M+ total raised. Mirador360 genetics-first platform. 10+ clinical readouts by end of 2027. Pipeline spans Crohn's, ulcerative colitis, RA, IPF.
About
Mirador Therapeutics is a precision immunology company with a genetics-first platform (Mirador360) that uses human genetic data to identify the most biologically validated targets and patient subpopulations for inflammatory and fibrotic diseases. The company closed a $250 million Series B in January 2026, bringing total funding above $650 million, with an ambitious pipeline targeting Crohn's disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis (IPF). Ten or more clinical readouts are expected by end of 2027.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.